Acuta Capital Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.6M Hold
4,685,912
– – 13.39% 2
2026
Q2
$21.5M Buy
4,685,912
+1,275,510
+37% +$5.31M 14.96% 2
2026
Q1
$11.8M Hold
3,410,402
– – 8.3% 3
2025
Q4
$8.25M Hold
3,410,402
– – 5.6% 5
2025
Q3
$6.48M Hold
3,410,402
– – 6.7% 4
2025
Q2
$6.38M Hold
3,410,402
– – 8.9% 3
2025
Q1
$6.07M Buy
3,410,402
+1,561,000
+84% +$4.08M 7.04% 4
2024
Q4
$5.83M Hold
1,849,402
– – 5.87% 6
2024
Q3
$3.81M Hold
1,849,402
– – 3.09% 13
2024
Q2
$2.7M Hold
1,849,402
– – 2.27% 17
2024
Q1
$4.33M Hold
1,849,402
– – 2.81% 15
2023
Q4
$3.74M Hold
1,849,402
– – 2.1% 20
2023
Q3
$8.95M Hold
1,849,402
– – 6% 3
2023
Q2
$12.6M Hold
1,849,402
– – 8.57% 2
2023
Q1
$13.4M Hold
1,849,402
– – 9.86% 2
2022
Q4
$19.6M Hold
1,849,402
– – 12.08% 1
2022
Q3
$26.1M Buy
1,849,402
+320,000
+21% +$4.21M 11.25% 2
2022
Q2
$18.8M Hold
1,529,402
– – 10.5% 2
2022
Q1
$26M Hold
1,529,402
– – 12.13% 2
2021
Q4
$36.9M Hold
1,529,402
– – 15.53% 1
2021
Q3
$44.9M Buy
+1,529,402
New +$46.6M 15.85% 1

Other funds holding WHWK

Acuta Capital Partners's WHWK Position: Q3 2026 in Review

Acuta Capital Partners held its Whitehawk Therapeutics (WHWK) position steady in Q3 2026 at 4,685,912 shares worth $17.6M. The position accounts for 13.39% of the portfolio, ranked #2.

Acuta Capital Partners first reported a position in WHWK in Q3 2021 and has held it in 21 quarters since. The position peaked at $44.9M in Q3 2021. 89 funds tracked by Wall St. Rank hold WHWK as of Q3 2026.

  • Acuta Capital Partners held 4,685,912 shares of Whitehawk Therapeutics worth $17.6M as of Q3 2026.
  • Acuta Capital Partners left its Whitehawk Therapeutics share count unchanged in Q3 2026.
  • Whitehawk Therapeutics made up 13.39% of Acuta Capital Partners's portfolio in Q3 2026, its #2 holding.
  • Acuta Capital Partners first reported a position in Whitehawk Therapeutics in Q3 2021 and has held it in 21 quarters since.
  • Acuta Capital Partners's Whitehawk Therapeutics position peaked at $44.9M in Q3 2021.
  • 89 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2026.

Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.